Abstract
Since the discovery that AIDS is caused by a retrovirus, HIV-1, enormous efforts have been made to develop new drugs that will combat this infectious disease. Although new conventional drugs have been found to block the replication of this virus efficiently, new mutant strains continuously arise, which escape the inhibitory effect of such drugs. Furthermore, since HIV-1 integrates its genome into that of the host cell, dormant viruses persist in infected individuals over long periods. Thus, great efforts are currently being made in many laboratories to develop alternative genetic approaches to inhibit the replication of this virus. With growing insight into the mechanism and regulation of HIV-1 replication, in the past decade, many strategies have been developed and proposed for clinical application to block HIV-1 replication inside the cell. Such strategies use either antiviral RNAs or proteins (for some recent reviews, see refs. 1–4). Antiviral strategies that employ RNAs have the advantage that they are less likely to be immunogenic than protein-based antiviral agents. However, protein-based systems have been engineered using inducible promoters that only become active upon HIV-1 infection. Although such antivirals have been proved to be very effective in vitro, their beneficial effect in vivo is very difficult to evaluate and still remains to be shown. In particular, the long latent period from infection to the onset of AIDS (up to 10 years or longer) makes it very difficult to evaluate the efficacy of a new drug.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bitton N, Gorochov G, Debre P, Eshhar Z. Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells. Front Biosci 1999; 4: D386 - D393.
Kohn DB, Sarver N. Gene therapy for HIV-1 infection. Adv Exp Med Biol 1996; 394: 421–428.
Palu G, Bonaguro R, Marcello A. In pursuit of new developments for gene therapy of human diseases. J Biotechnol 1999; 68: 1–13.
Pomerantz RI, Trono D. Genetic therapies for HIV infections: promise for the future. AIDS 1995; 9: 985–993.
Smith C, Sullenger BA. AIDS and HIV infection. Mol Cell Biol Hum Dis Ser 1995; 5: 195–236.
Baltimore D. Intracellular immunization. Nature 1988; 235: 395–396.
Caputo A, Grossi MP, Rossi C, et al. The tat gene and protein of the human immunodeficiency virus type 1. N Microbiol 1995; 18: 87–110.
Lisziewicz J. Tar decoys and trans-dominant gag mutant for HIV-1 gene therapy. Antibiot Chemother 1996; 48: 192–197.
Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol 1994; 56: 203–209.
Marasco WA. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther 1997; 4: 11–15.
Rondon IJ, Marasco WA. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol 1997; 51: 257–283.
Earnshaw DJ, Gait MJ. Progress toward the structure and therapeutic use of the hairpin ribozyme. Antisense Nucleic Acid Drug Dev 1997; 7: 403–411.
Hampel A. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Prog Nucleic Acid Res Mol Biol 1998; 58: 1–39.
James W. The use of ribozymes in gene therapy approaches to AIDS. Recent Results Cancer Res 1998; 144: 139–146.
Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ. Therapeutic applications of ribozymes. Pharmacol Ther 1995; 68: 247–267.
Macpherson JL, Ely JA, Sun LQ, Symonds GP. Ribozymes in gene therapy of HIV-1. Front Biosci 1999; 4: D497 - D505.
Rossi JJ. Therapeutic applications of catalytic antisense mas (ribozymes). Ciba Found Symp 1997; 209: 195–204.
Sun LQ, Ely JA, Gerlach W, Symonds G. Anti-HIV ribozymes. Mol Biotechnol 1997; 7: 241–251.
Dornburg R. Reticuloendotheliosis viruses and derived vectors. Gene Ther 1995; 2: 301–310.
Gunzburg WH, Salmons B. Development of retroviral vectors as safe, targeted gene delivery systems [review]. J Mol Med 1996; 74: 171–182.
Miller AD. Retrovirus packaging cells. Hum Gene Ther 1990; 1: 5–14.
Mitani K, Caskey CT. Delivering therapeutic genes-matching approach and application. Trends Biotechnol 1993; 11: 162–166.
Turchetto L, Benati C, Mattei S, et al. An approach to HIV gene therapy by transduction of multifunctional retroviral vectors in primary human t lymphocytes. J Biol Regul Homeost Agents 1997; 11: 79–81.
Warner JF, Jolly D, Mento S, Galpin J, Haubrich R, Merritt J. Retroviral vectors for HIV immunotherapy. Ann NY Acad Sci 1995; 772: 105–116.
Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463–8471.
Klimatcheva E, Rosenblatt JD, Planelles V. Lentiviral vectors and gene therapy. Front Biosci 1999; 4: D481 - D496.
Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 1996; 272: 263–267.
Parolin C, Sodroski J. A defective HIV-1 vector for gene transfer to human lymphocytes. J Mol Med 1995; 73: 279–288.
Poeschla E, Corbeau P, Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996; 93: 11395–11399.
Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873–9880.
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871–875.
Amado RG, Mitsuyasu RT, Zack JA. Gene therapy for the treatment of AIDS: animal models and human clinical experience. Front Biosci 1999; 4: D468 - D475.
Jamieson BD, Aldrovandi GM, Zack JA. The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS. Semin Immunol 1996; 8: 215–221.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Dornburg, R., Pomerantz, R.J. (2002). Gene Therapy for HIV-1 Infection. In: Jacobson, J.M. (eds) Immunotherapy for Infectious Diseases. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-171-8_13
Download citation
DOI: https://doi.org/10.1007/978-1-59259-171-8_13
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9681-9
Online ISBN: 978-1-59259-171-8
eBook Packages: Springer Book Archive